Evelo Biosciences (EVLO)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Jul 25, 2024 03:15 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Evelo Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 48 | 68 | 69 | 78 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 4 | 3 | 2 | 3 |
Total Current Assets | NA | 52 | 71 | 71 | 81 |
Net Property & Equipment | NA | 5 | 7 | 7 | 8 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 2 |
Total Assets | NA | 64 | 88 | 91 | 91 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 2 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 8 | 13 | 16 | 9 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 1 | 0 | 0 |
Total Current Liabilities | NA | 12 | 17 | 20 | 10 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 8 | 8 | 0 | 1 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 44 | 47 | 30 | 20 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 0 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 69 | 79 | 60 | 31 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 524 | 423 | 323 | 259 |
Retained Earnings | NA | -529 | -415 | -293 | -199 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -5 | 9 | 30 | 60 |
Total Liabilities & Shareholder's Equity | NA | 64 | 88 | 91 | 91 |
Total Common Equity | 0 | -5 | 9 | 30 | 60 |
Shares Outstanding | 18.90 | 5.40 | 2.60 | 2.30 | 1.60 |
Book Value Per Share | 0.00 | -0.92 | 3.33 | 13.26 | 37.63 |
Fiscal Year End for Evelo Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | 17 | -99,991 |
Receivables | NA | NA | NA | 0 | NA |
Notes Receivable | NA | NA | NA | 0 | NA |
Inventories | NA | NA | NA | 0 | NA |
Other Current Assets | NA | NA | NA | 2 | 4 |
Total Current Assets | NA | NA | NA | 19 | 11 |
Net Property & Equipment | NA | NA | NA | 1 | 2 |
Investments & Advances | NA | NA | NA | 0 | NA |
Other Non-Current Assets | NA | NA | NA | 0 | NA |
Deferred Charges | NA | NA | NA | 0 | NA |
Intangibles | NA | NA | NA | 0 | NA |
Deposits & Other Assets | NA | NA | NA | 1 | 1 |
Total Assets | NA | NA | NA | 21 | 21 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | 0 | NA |
Accounts Payable | NA | NA | NA | 1 | 4 |
Current Portion Long-Term Debt | NA | NA | NA | 34 | 44 |
Current Portion Capital Leases | NA | NA | NA | 0 | NA |
Accrued Expenses | NA | NA | NA | 5 | 5 |
Income Taxes Payable | NA | NA | NA | 0 | NA |
Other Current Liabilities | NA | NA | NA | 1 | 0 |
Total Current Liabilities | NA | NA | NA | 40 | 56 |
Mortgages | NA | NA | NA | 0 | NA |
Deferred Taxes/Income | NA | NA | NA | 8 | 8 |
Convertible Debt | NA | NA | NA | 0 | NA |
Long-Term Debt | NA | NA | NA | 0 | NA |
Non-Current Capital Leases | NA | NA | NA | 0 | NA |
Other Non-Current Liabilities | NA | NA | 0 | 0 | |
Minority Interest (Liabilities) | NA | NA | NA | 0 | NA |
Total Liabilities | NA | NA | NA | 47 | 67 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | 0 | NA |
Common Stock (Par) | NA | NA | NA | 0 | 0 |
Capital Surplus | NA | NA | NA | 561 | 530 |
Retained Earnings | NA | NA | NA | -588 | -576 |
Other Equity | NA | NA | NA | 0 | NA |
Treasury Stock | NA | NA | NA | 0 | NA |
Total Shareholder's Equity | NA | NA | NA | -27 | -46 |
Total Liabilities & Shareholder's Equity | NA | NA | NA | 21 | 21 |
Total Common Equity | 0 | 0 | 0 | -27 | 99,953 |
Shares Outstanding | 18.90 | 18.90 | 18.90 | 18.80 | 5.60 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | -1.42 | 17,848.73 |